Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsJan‐Niklas Eckardt, Jan Moritz Middeke, Sebastian Scholl et al.|Journal of Hematology & Oncology|2022Cited by 58
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classificationJan‐Niklas Eckardt, Christoph Röllig, Marius Bill et al.|Leukemia|2023Cited by 36
Impact of <i>PTPN11</i> mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaSebastian Stasik, Jan‐Niklas Eckardt, Michael Krämer et al.|Blood Advances|2021Cited by 35
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcomeJan‐Niklas Eckardt, Christian Thiede, Sebastian Stasik et al.|Blood Cancer Journal|2023Cited by 34
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan‐Niklas Eckardt, Christian Thiede, Sebastian Stasik et al.|Leukemia|2023Cited by 14